UK Markets closed

ABIVAX Société Anonyme (0RA9.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
7.05+0.09 (+1.30%)
At close: 03:13PM BST

ABIVAX Société Anonyme

5, rue de la Baume
Paris 75008
33 1 53 83 08 41

Full-time employees24

Key executives

NameTitlePayExercisedYear born
Prof. Hartmut J. EhrlichChief Exec. Officer456.81kN/AN/A
Dr. Philippe Pouletty M.D., Ph.D.Founder & DirectorN/AN/A1958
Mr. Didier BlondelEVP, CFO & Board Sec.N/AN/AN/A
Ms. Raquel LizarragaInvestor Relations Mang.N/AN/AN/A
Ms. Regina JehleVP CommunicationsN/AN/AN/A
Anne PascardHR Mang.N/AN/AN/A
Mr. Pierre Courteille M.B.A.Chief Commercial Officer & VP of Bus. Devel.N/AN/AN/A
Mr. Paul GinesteVP Clinical OperationsN/AN/AN/A
Mr. Alain ChevallierSr. AdvisorN/AN/A1953
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.


ABIVAX Société Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France. Its principal products include ABX464 that is in Phase IIb clinical trials for the treatment of ulcerative colitis and Crohn's Disease, as well as for COVID-19; Phase IIa clinical trial for the treatment of rheumatoid arthritis diseases; and has completed Phase IIa clinical trial for the treatment of viral remission in patients with HIV. It also develops ABX 196, an immune enhancer candidate that is in Phase 1/2 clinical trials for the treatment of hepatocellular cancer. In addition, the company engages in the research programs for the treatment of Dengue fever, influenza, and respiratory syncytial virus. ABIVAX Société Anonyme has license contracts with the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. The company was incorporated in 2013 and is headquartered in Paris, France.

Corporate governance

ABIVAX Société Anonyme’s ISS governance QualityScore as of 1 February 2023 is 9. The pillar scores are Audit: 10; Board: 8; Shareholder rights: 9; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.